Valuation: Arcellx, Inc.

Market Cap 6.75B 6.05B 5.56B 5.04B 9.42B 641B 9.6B 66.33B 26.63B 337B 25.34B 24.8B 1,063B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.63B 5.18B 4.69B 8.77B 597B 8.93B 61.73B 24.78B 314B 23.58B 23.08B 990B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 32.9
Extreme 32.9
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Manager TitleAgeSince
Chief Executive Officer 56 -
Director TitleAgeSince
Director/Board Member 56 -
Date Insider Type Main position Quantity % Market Cap. Importance
4/28/26 Tender

Director

216,666 0.3705%
4/28/26 Tender

Chief Executive Officer

5,603,097 9.5813%
4/28/26 Issuer sale

Director

76,234 0.1304%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+33.76%+262.43% 6.75B
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.08%+4.26%+50.82%+173.78% 39.94B
Weighted average by Cap. +0.01%+3.58%+49.18%+163.92%

Financials

2024 2025
Net sales 107.94 96.67 88.92 80.57 150.6 10.25K 153.42 1.06K 425.67 5.39K 405.07 396.46 17K 22.29 19.96 18.36 16.64 31.1 2.12K 31.68 218.94 87.89 1.11K 83.64 81.86 3.51K
Net income -107M -96.14M -88.43M -80.13M -150M -10.19B -153M -1.05B -423M -5.36B -403M -394M -16.91B -229M -205M -189M -171M -319M -21.74B -325M -2.25B -903M -11.43B -859M -841M -36.06B
Net Debt -572M -512M -471M -427M -798M -54.27B -812M -5.62B -2.25B -28.55B -2.15B -2.1B -90.03B -468M -419M -386M -349M -653M -44.45B -665M -4.6B -1.85B -23.38B -1.76B -1.72B -73.74B
Projected Income Statement - Annual - Arcellx, Inc.
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arcellx, Inc.
  1. Stock Market
  2. Stocks
  3. ACLX Stock